Reirradiation using helical tomotherapy-based hypofractionated stereotactic radiotherapy for 19 brain metastases after the second recurrence of distant brain failure: a case report and literature review.
Tao Wang, Hongfu Zhao, Rafal Suwinski, Guanghui Cheng, Wei Guan
{"title":"Reirradiation using helical tomotherapy-based hypofractionated stereotactic radiotherapy for 19 brain metastases after the second recurrence of distant brain failure: a case report and literature review.","authors":"Tao Wang, Hongfu Zhao, Rafal Suwinski, Guanghui Cheng, Wei Guan","doi":"10.21037/tlcr-2024-1151","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A definitive optimal oncologic care regimen for recurrent multiple brain metastases (BMs) has yet to be established, and the accrual of high-quality evidence pertaining to helical tomotherapy-based stereotactic radiotherapy (HT-SRT) in patients with BMs is needed.</p><p><strong>Case description: </strong>We treated a 64-year-old male smoker initially diagnosed with non-small cell lung cancer (NSCLC) with BMs, and the initial schedule involved administering linear accelerator-based hypofractionated stereotactic radiotherapy (Linac-HSRT) targeting 6 intracranial lesions. Further chemotherapy was declined due to intolerance after one cycle of paclitaxel-albumin/carboplatin. Distant brain failure (DBF) and extracranial progression emerged 3 months subsequent to the initial SRT, and helical tomotherapy-based hypofractionated stereotactic radiotherapy (HT-HSRT) was replanned to 4 BMs, while helical tomotherapy-based intensity-modulated radiotherapy was employed for the extracranial lesions. Nevertheless, reirradiation with hippocampal-sparing HT-HSRT and simultaneous memantine approach were imminently delivered for confirmed DBF, as 19 newly identified intact intracranial lesions were observed at 5 months posttreatment. As assessed by the Hopkins Verbal Learning Test Revised Total Recall test, neither severe symptomatic radionecrosis (RN) nor neurocognitive dysfunction has manifested thus far, representing a survival period of 20.5 months. In the literature review, SRT delivery schedule to BMs, strategies for managing recurrent BMs and addressing RN, along with 6 summarized published studies of HT-SRT for BM were discussed.</p><p><strong>Conclusions: </strong>We posit that the administration of repeated SRT for recurrent BMs in a short-term interval may be viable, yet randomized, robust analyses are imperative to ascertain the potential benefits of HT-SRT in preserving neurocognition and confirm the efficacy of memantine and hippocampal avoidance during SRT.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 1","pages":"272-286"},"PeriodicalIF":4.0000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826268/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-2024-1151","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: A definitive optimal oncologic care regimen for recurrent multiple brain metastases (BMs) has yet to be established, and the accrual of high-quality evidence pertaining to helical tomotherapy-based stereotactic radiotherapy (HT-SRT) in patients with BMs is needed.
Case description: We treated a 64-year-old male smoker initially diagnosed with non-small cell lung cancer (NSCLC) with BMs, and the initial schedule involved administering linear accelerator-based hypofractionated stereotactic radiotherapy (Linac-HSRT) targeting 6 intracranial lesions. Further chemotherapy was declined due to intolerance after one cycle of paclitaxel-albumin/carboplatin. Distant brain failure (DBF) and extracranial progression emerged 3 months subsequent to the initial SRT, and helical tomotherapy-based hypofractionated stereotactic radiotherapy (HT-HSRT) was replanned to 4 BMs, while helical tomotherapy-based intensity-modulated radiotherapy was employed for the extracranial lesions. Nevertheless, reirradiation with hippocampal-sparing HT-HSRT and simultaneous memantine approach were imminently delivered for confirmed DBF, as 19 newly identified intact intracranial lesions were observed at 5 months posttreatment. As assessed by the Hopkins Verbal Learning Test Revised Total Recall test, neither severe symptomatic radionecrosis (RN) nor neurocognitive dysfunction has manifested thus far, representing a survival period of 20.5 months. In the literature review, SRT delivery schedule to BMs, strategies for managing recurrent BMs and addressing RN, along with 6 summarized published studies of HT-SRT for BM were discussed.
Conclusions: We posit that the administration of repeated SRT for recurrent BMs in a short-term interval may be viable, yet randomized, robust analyses are imperative to ascertain the potential benefits of HT-SRT in preserving neurocognition and confirm the efficacy of memantine and hippocampal avoidance during SRT.
期刊介绍:
Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.